Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection - Trial NCT06347887
Access comprehensive clinical trial information for NCT06347887 through Pure Global AI's free database. This phase not specified trial is sponsored by Singlera Genomics Inc. and is currently Completed. The study focuses on Colorectal Cancer. Target enrollment is 1965 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Singlera Genomics Inc.
Timeline & Enrollment
N/A
May 31, 2021
Jan 16, 2024
Primary Outcome
Sensitivity for colorectal cancer with ColonAiQ test,Specificity for colorectal cancer with ColonAiQ test
Summary
The DNA methylation targets in preoperative plasma samples of the subjects will be detected
 by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by
 compared with the clinical diagnosis evidence.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06347887
Non-Device Trial